Voxvoganan: meta-analysis of COVID-19 studies

All studies Viral clearance RCTs All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−29%

Viral clearance (1)−29%

RCTs (1)−29%

Early (1)−29%

00.511.5+

← Voxvoganan
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

October 2026

Voxvoganan COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lütken (DB RCT)−29%1.29 · 0.20–8.28viral load11 (n)12 (n)

Early treatment−29%1.29 · 0.20–8.2811 (n)12 (n)29% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8

All studies−29%1.29 · 0.20–8.2811 (n)12 (n)29% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+

Rotate screen for more detailsIncrease width for more details

← Voxvoganan
reduces riskVoxvoganan
increases risk →

October 2026

Voxvoganan COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lütken (DB RCT)−29%1.29 · 0.20–8.28viral load11 (n)12 (n)

Early treatment−29%1.29 · 0.20–8.2811 (n)12 (n)29% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8

All studies−29%1.29 · 0.20–8.2811 (n)12 (n)29% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+

Rotate screen for more detailsIncrease width for more details

← Voxvoganan
reduces riskVoxvoganan
increases risk →

October 2026

Voxvoganan COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lütken (DB RCT)−29%1.29 · 0.20–8.28viral load11 (n)12 (n)

Early treatment−29%1.29 · 0.20–8.2811 (n)12 (n)29% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8

All studies−29%1.29 · 0.20–8.2811 (n)12 (n)29% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.800.511.52+

Rotate screen for more detailsIncrease width for more details

← Voxvoganan
reduces riskVoxvoganan
increases risk →

October 2026

Voxvoganan COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lütken (DB RCT)−29%1.29 · 0.20–8.28viral load11 (n)12 (n) Lütken (DB RCT)6%0.94 · 0.08–11.36viral load11 (n)12 (n) Lütken (DB RCT)−93%1.93 · 0.12–31.01viral load11 (n)12 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Voxvoganan
reduces riskVoxvoganan
increases risk →